Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) | Zendy

Lars Gullestad | Zendy; Thor Ueland | Zendy; John Kjekshus | Zendy; Ståle H. Nymo | Zendy; J. Hulthe | Zendy; Pieter Muntendam | Zendy; Aram Adourian | Zendy; Michael Böhm | Zendy; Dirk J. van Veldhuisen | Zendy; Michel Komajda | Zendy; John G.F. Cleland | Zendy; John Wikstrand | Zendy; John J.V. McMurray | Zendy; Pål Aukrust | Zendy

Open Access

Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

Author(s) -

Lars Gullestad,

Thor Ueland,

John Kjekshus,

Ståle H. Nymo,

J. Hulthe,

Pieter Muntendam,

Aram Adourian,

Michael Böhm,

Dirk J. van Veldhuisen,

Michel Komajda,

John G.F. Cleland,

John Wikstrand,

John J.V. McMurray,

Pål Aukrust

Publication year - 2012

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1093/eurheartj/ehs077

Subject(s) - rosuvastatin , medicine , heart failure , hazard ratio , rosuvastatin calcium , myocardial infarction , cardiology , placebo , clinical endpoint , confidence interval , statin , gastroenterology , randomized controlled trial , pathology , alternative medicine

To investigate whether plasma galectin-3, a mediator of fibrogenesis, can identify patients with chronic heart failure (HF) for whom statins are effective.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research